Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 297

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

Open access
D'Angelo, Sandra P, Araujo, Dejka M, Abdul Razak, Albiruni R, Agulnik, Mark, Attia, Steven, Blay, Jean-Yves, Carrasco Garcia, Irene, Charlson, John A, Choy, Edwin, Demetri, George D, Druta, Mihaela, Forcade, Edouard, Ganjoo, Kristen N, Glod, John, Keedy, Vicki L, Le Cesne, Axel, Liebner, David A, Moreno, Victor, Pollack, Seth M, Schuetze, Scott M, Schwartz, Gary K, Strauss, Sandra J, Tap, William D, Thistlethwaite, Fiona, Valverde Morales, Claudia Maria, Wagner, Michael J, Wilky, Breelyn A, McAlpine, Cheryl, Hudson, Laura, Navenot, Jean-Marc, Wang, Tianjiao, Bai, Jane, Rafail, Stavros, Wang, Ruoxi, Sun, Amy, Fernandes, Lilliam, Van Winkle, Erin, Elefant, Erica, Lunt, Colin, Norry, Elliot, Williams, Dennis, Biswas, Swethajit, Van Tine, Brian A·2024·The Lancet

Abstract

Summary Background Afamitresgene autoleucel (afami-cel) showed acceptable safety and promising efficacy in a phase 1 trial (NCT03132922). This study evaluated afami-cel’s efficacy in human leukocyte antigen (HLA)-A*02–positive patients with melanoma-associated antigen A4 (MAGE-A4)-expressing advanced synovial sarcoma or myxoid/round cell liposarcomas (MRCLS). Methods Cohort 1 of this ongoing, single-arm, open-label, phase 2 trial evaluated a single intravenous afami-cel dose after lymphodepletion in HLA-A*02–positive adult patients with metastatic/unresectable synovial sarcoma or MRCLS expressing MAGE-A4 who had received ≥1 prior line of anthracycline and/or ifosfamide-containing chemotherapy. Primary endpoint was overall response rate in cohort 1, determined by a blinded committee using Response Evaluation Criteria in Solid Tumours version 1·1 in the modified intent-to-treat population. Adverse events (AEs), including those of special interest (cytokine release syndrome, prolonged/pan-cytopenia, neurotoxicity) were monitored. Trial is registered at ClinicalTrials.gov, number NCT04044768. Findings Between 17 December 2019 and 27 July 2021, 52 patients with cytogenetically confirmed synovial sarcoma (n=44) and MRCLS (n=8) were enrolled and received afami-cel in cohort 1. Baseline median MAGE-A4 expression P-score was 83·5 (IQR 62–99) overall and 89·5 in patients with synovial sarcoma; H-score was 231·5 (IQR 174–294) overall and 256·5 in patients with synovial sarcoma. Patients were heavily pre-treated (median 3 [IQR 2–4] prior lines of systemic therapy). Overall response rate was 37% (19 of 52; 95% CI 23·62–51·04) overall, 39% (17 of 44) in synovial sarcoma, and 25% (2 of 8) in MRCLS; median follow-up time, 32·6 months (IQR 29–36). Cytokine release syndrome occurred in 71% (37 of 52) of patients (one grade 3 event). Cytopenias were the most common grade ≥3 AEs (lymphopenia in 50 [96%], neutropenia 44 [85%], leukopenia 42 [81%] of 52). Interpretation Afami-cel treatment resulted in durable responses in heavily pre-treated HLA-A*02–positive patients with MAGE-A4–expressing synovial sarcoma. Grade 1/2 cytokine release syndrome and grade 3/4 haematologic toxicities were common. Funding Adaptimmune.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)00319-2

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 297

Metadata

Authors
D'Angelo, S. P., Araujo, D. M., Abdul Razak, A. R., Agulnik, M., Attia, S., Blay, J.-Y., Carrasco Garcia, I., Charlson, J. A., Choy, E., Demetri, G. D., Druta, M., Forcade, E., Ganjoo, K. N., Glod, J., Keedy, V. L., Le Cesne, A., Liebner, D. A., Moreno, V., Pollack, S. M., Schuetze, S. M., Schwartz, G. K., Strauss, S. J., Tap, W. D., Thistlethwaite, F., Valverde Morales, C. M., Wagner, M. J., Wilky, B. A., McAlpine, C., Hudson, L., Navenot, J.-M., Wang, T., Bai, J., Rafail, S., Wang, R., Sun, A., Fernandes, L., Van Winkle, E., Elefant, E., Lunt, C., Norry, E., Williams, D., Biswas, S., & Van Tine, B. A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-04
Volume
403
Issue
10435
Pages
1460-1471
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4393238683
Cited by
297
References
20
FWCI
45.43
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00319-2
The paper
D'Angelo, S. P., Araujo, D. M., Abdul Razak, A. R., Agulnik, M., Attia, S., Blay, J.-Y., Carrasco Garcia, I., Charlson, J. A., Choy, E., Demetri, G. D., Druta, M., Forcade, E., Ganjoo, K. N., Glod, J., Keedy, V. L., Le Cesne, A., Liebner, D. A., Moreno, V., Pollack, S. M., . . . Van Tine, B. A. (2024). Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(24)00319-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.